Related references
Note: Only part of the references are listed.PIK3CA, BRAF and KRAS mutations and outcome prediction in chemorefractory metastatic colorectal cancer (mCRC) patients treated with EGFR targeting monoclonal antibodies (MoAbs): results of a European Consortium
S. Tejpar et al.
EJC SUPPLEMENTS (2009)
A meta-analysis of the CRYSTAL and OPUS studies combining cetuximab with chemotherapy (CT) as 1st-line treatment for patients (pts) with metastatic colorectal cancer (mCRC): Results according to KRAS and BRAF mutation status
E. Van Cutsem et al.
EJC SUPPLEMENTS (2009)
Genetic pathways to colorectal cancer
Isabel A. Lea et al.
MUTATION RESEARCH-FUNDAMENTAL AND MOLECULAR MECHANISMS OF MUTAGENESIS (2009)
PIK3CA mutation in colorectal cancer:: Relationship with genetic and epigenetic alterations
Katsuhiko Nosho et al.
NEOPLASIA (2008)
Human epidermal growth factor receptor 2 testing recommendation - In reply
Antonio C. Wolff et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
Association of k-ras, b-raf, and p53 status with the treatment effect of bevacizumab
WL Ince et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2005)
Share Paper
